Trending: Novartis Shares Climb on Guidance Lift
1240 GMT - Novartis is among the most mentioned companies across news items over the past 12 hours, according to Factiva data. The Swiss pharma giant's shares surged after it lifted its full-year guidance on profit and sales that rose in the first quarter. The stock traded 5.4% higher at CHF92.03 earlier, making it one of today's best performers in the Stoxx 600 index. Shares of Novartis grew 7.2% year-to-date. In addition to Novartis's first-quarter results beating expectations, the company also confirmed it isn't experiencing any drug shortages following its strategic refocus on specialty medicines in its four core therapeutic areas, which it undertook last year, Chief Financial Officer Harry Kirsch said in a press call. Dow Jones & Co. owns Factiva. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 23, 2024 08:55 ET (12:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening In the Markets This Week
-
What Does Nvidia’s Stock Split Mean for Investors?
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Markets Brief: Friday’s Job Report in Focus
-
These Stocks Are (Still) Powering the Bull Market
-
Nio Earnings: Revenue and Loss Largely In Line, but Vehicle Margin Missed Amid Price Competition
-
The Best Biotech Stocks to Buy
-
After Earnings, Is Marvell Stock a Buy, a Sell, or Fairly Valued?
-
Nvidia Raised Its Dividend — but There’s a Catch
-
Lululemon Earnings: On Track to Meet Expectations Despite Slowdown In Americas
-
What Is Driving Small-Cap Stock Underperformance?
-
After Earnings, Is Zscaler Stock a Buy, a Sell, or Fairly Valued?
-
ASML Fair Value Raised as Outlook Improves